Larimar Therapeutics Q3 net loss widens

Larimar Therapeutics

05/11/2025 12:17

Overview

Larimar reports Q3 net loss of $47.7 mln, driven by increased R&D expenses

Company modifies nomlabofusp dosing to reduce anaphylaxis risk

BLA submission for nomlabofusp targeted for Q2 2026

Outlook

Larimar targets BLA submission for nomlabofusp in Q2 2026

Company plans U.S. launch of nomlabofusp in early 2027

Larimar implementing modified dosing regimen to reduce anaphylaxis risk

Result Drivers

Research and development expenses for the third quarter of 2025 were $44.9 million compared to $13.9 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.61
Q3 Net Income
-$47.71 mln
Q3 Basic EPS
-$0.61
Q3 Income From Operations
-$49.49 mln
Q3 Operating Expenses
$49.49 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Larimar Therapeutics Inc is $17.00, about 77.6% above its November 4 closing price of $3.80

Press Release: ID:nGNXbKrz8r

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)